Skip to main content
. Author manuscript; available in PMC: 2020 Aug 11.
Published in final edited form as: Clin Pharmacol Ther. 2017 Nov 20;103(1):67–76. doi: 10.1002/cpt.871

Figure 4.

Figure 4

Evolution of estimated clinical outcome of OS benefit-risk over time for MM patients. The starting point for the blue line at year 2001 is taken as the estimated median OS of newly diagnosed MM patients prior to 199647 with the ratio of risk to benefit the same as that of thalidomide plus dexamethasone.30